Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,totalAssets,commonStock,retainedEarnings,treasuryStock,otherAssets,cash,totalCurrentLiabilities,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,longTermInvestments,shortTermInvestments,netReceivables,accountsPayable,otherCurrentLiab,otherLiab,deferredLongTermLiab,investments,changeToLiabilities,totalCashflowsFromInvestingActivities,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,capitalExpenditures,repurchaseOfStock,otherCashflowsFromFinancingActivities,WC,language,region,quoteType,triggerable,quoteSourceName,currency,regularMarketChangePercent,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,epsCurrentYear,priceEpsCurrentYear,gmtOffSetMilliseconds,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,priceHint,shortName,longName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,marketState,exchange,market,twoHundredDayAverageChangePercent,marketCap,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,esgPopulated,tradeable,exchangeDataDelayedBy,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (May 27, 2021) 4","Short Ratio (May 27, 2021) 4","Short % of Float (May 27, 2021) 4","Short % of Shares Outstanding (May 27, 2021) 4","Shares Short (prior month Apr 29, 2021) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,INZY,148889000.0,23483100,6403000,,-11050000,,-11050000,4569000,0,-10972000,-10972000,,,,,,0,0,10972000,0,-78000,,-11050000,-11050000,251001000.0,10026000.0,148889000.0,158915000.0,2000.0,-102126000.0,12000.0,3297000.0,16486000.0,6832000.0,12000.0,5029000.0,148041000.0,2548000.0,128600000.0,122000.0,1709000.0,,,,661000.0,-1373000.0,573000.0,249000.0,-1836000.0,249000.0,-11554000.0,-12376000.0,158000.0,1725000.0,-88000.0,,,141209000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.6861234,14.66 - 15.74,15.42,15.01,0.0,8,32,finmb_568596329,NasdaqGS,USD,61926,24357,0.6499996,0.044796664,14.51 - 30.96,-15.799999,-0.5103359,14.51,30.96,1620799200,1630499400,1631017800,-2.29,-6.620087,-14400000,16.676428,-1.516428,-0.09093242,17.86953,-2.7095299,2,"Inozyme Pharma, Inc.","Inozyme Pharma, Inc.",15.16,1630526402,-0.26000023,15.19,15.74,14.66,46772,PRE,NMS,us_market,-0.1516285,356003808,15,America/New_York,EDT,False,False,0,,,,30.96,14.51,16.68,17.87,61.93k,24.36k,23.48M,,4.71M,8.89%,94.76%,892.23k,21.11,5.48%,3.80%,1.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.39%,-64.23%,,,,,-59.76M,-59.74M,,,145.09M,6.18,3.87M,2.60,21.67,,-42.09M,-35.3M,Value,02210,Healthcare,38,"Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Boston,857 330 4340,MA,1609372800,United States,http://www.inozyme.com,86400,321 Summer Street,Biotechnology,Suite 400
t-1,INZY,158103000.0,23483100,6382000,,-11118000,,-11118000,4889000,0,-11271000,-11271000,,,,,,0,0,11271000,0,153000,,-11118000,-11118000,249175000.0,11260000.0,158103000.0,169363000.0,2000.0,-91076000.0,2000.0,3537000.0,28040000.0,9973000.0,2000.0,2648000.0,150979000.0,12199000.0,119657000.0,155000.0,3069000.0,279000.0,1287000.0,,-20142000.0,354000.0,-19957000.0,-986000.0,-1644000.0,249000.0,-31818000.0,-10875000.0,123000.0,1410000.0,185000.0,-986000.0,,141006000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.6861234,14.66 - 15.74,15.42,15.01,0.0,8,32,finmb_568596329,NasdaqGS,USD,61926,24357,0.6499996,0.044796664,14.51 - 30.96,-15.799999,-0.5103359,14.51,30.96,1620799200,1630499400,1631017800,-2.29,-6.620087,-14400000,16.676428,-1.516428,-0.09093242,17.86953,-2.7095299,2,"Inozyme Pharma, Inc.","Inozyme Pharma, Inc.",15.16,1630526402,-0.26000023,15.19,15.74,14.66,46772,PRE,NMS,us_market,-0.1516285,356003808,15,America/New_York,EDT,False,False,0,,,,30.96,14.51,16.68,17.87,61.93k,24.36k,23.48M,,4.71M,8.89%,94.76%,892.23k,21.11,5.48%,3.80%,1.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.39%,-64.23%,,,,,-59.76M,-59.74M,,,145.09M,6.18,3.87M,2.60,21.67,,-42.09M,-35.3M,Value,02210,Healthcare,38,"Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Boston,857 330 4340,MA,1609372800,United States,http://www.inozyme.com,86400,321 Summer Street,Biotechnology,Suite 400
t-2,INZY,167916000.0,23483100,25174000,,-28095000,,-28095000,3142000,0,-28316000,-28316000,,,,,,0,0,28316000,0,221000,,-28095000,-28095000,247872000.0,11077000.0,167916000.0,178993000.0,2000.0,-79958000.0,,354000.0,59858000.0,9814000.0,,2455000.0,163977000.0,12207000.0,99644000.0,252000.0,3665000.0,,1263000.0,,-99081000.0,1290000.0,-99666000.0,118861000.0,-2205000.0,117006000.0,8994000.0,-10201000.0,43000.0,18766000.0,-585000.0,-986000.0,1855000.0,154163000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.6861234,14.66 - 15.74,15.42,15.01,0.0,8,32,finmb_568596329,NasdaqGS,USD,61926,24357,0.6499996,0.044796664,14.51 - 30.96,-15.799999,-0.5103359,14.51,30.96,1620799200,1630499400,1631017800,-2.29,-6.620087,-14400000,16.676428,-1.516428,-0.09093242,17.86953,-2.7095299,2,"Inozyme Pharma, Inc.","Inozyme Pharma, Inc.",15.16,1630526402,-0.26000023,15.19,15.74,14.66,46772,PRE,NMS,us_market,-0.1516285,356003808,15,America/New_York,EDT,False,False,0,,,,30.96,14.51,16.68,17.87,61.93k,24.36k,23.48M,,4.71M,8.89%,94.76%,892.23k,21.11,5.48%,3.80%,1.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.39%,-64.23%,,,,,-59.76M,-59.74M,,,145.09M,6.18,3.87M,2.60,21.67,,-42.09M,-35.3M,Value,02210,Healthcare,38,"Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Boston,857 330 4340,MA,1609372800,United States,http://www.inozyme.com,86400,321 Summer Street,Biotechnology,Suite 400
t-3,INZY,-50019000.0,23483100,7760000,,-9473000,,-9473000,1788000,0,-9548000,-9548000,,,,,,0,0,9548000,0,75000,,-9473000,-9473000,1831000.0,6965000.0,-50019000.0,68511000.0,,-51863000.0,13000.0,3005000.0,50863000.0,6727000.0,13000.0,846000.0,64660000.0,,13004000.0,82000.0,1399000.0,,238000.0,2650000.0,5919000.0,-214000.0,5852000.0,31932000.0,943000.0,149000.0,29151000.0,-8633000.0,26000.0,85000.0,-67000.0,-986000.0,-1855000.0,57933000.0,en-US,US,EQUITY,True,Nasdaq Real Time Price,USD,-1.6861234,14.66 - 15.74,15.42,15.01,0.0,8,32,finmb_568596329,NasdaqGS,USD,61926,24357,0.6499996,0.044796664,14.51 - 30.96,-15.799999,-0.5103359,14.51,30.96,1620799200,1630499400,1631017800,-2.29,-6.620087,-14400000,16.676428,-1.516428,-0.09093242,17.86953,-2.7095299,2,"Inozyme Pharma, Inc.","Inozyme Pharma, Inc.",15.16,1630526402,-0.26000023,15.19,15.74,14.66,46772,PRE,NMS,us_market,-0.1516285,356003808,15,America/New_York,EDT,False,False,0,,,,30.96,14.51,16.68,17.87,61.93k,24.36k,23.48M,,4.71M,8.89%,94.76%,892.23k,21.11,5.48%,3.80%,1.44M,,,,,,0.00%,,,,,"Dec 30, 2020","Mar 30, 2021",0.00%,0.00%,-37.39%,-64.23%,,,,,-59.76M,-59.74M,,,145.09M,6.18,3.87M,2.60,21.67,,-42.09M,-35.3M,Value,02210,Healthcare,38,"Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.",Boston,857 330 4340,MA,1609372800,United States,http://www.inozyme.com,86400,321 Summer Street,Biotechnology,Suite 400
